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contact activation,12 but bleeding and platelet activation
are still present.13-17 Therefore other causes of platelet
activation might still exist.
One of these causes could be the use of roller or cen-
trifugal pumps, indispensable in many extracorporeal
circuits. Pumps may indirectly activate platelets by
causing lysis of red blood cells, with subsequent release
of adenosine diphosphate (ADP). Pumps have therefore
continuously been improved to reduce hemolysis.
Nevertheless, the problem of platelet activation in extra-
corporeal systems has not been resolved.
Little attention has been paid to the possibility that
intermittent increases in shear stress caused by the
pumping can activate platelets more directly. Effects of
shear stress on platelet behavior have mainly been stud-
ied in vitro with viscometers18-21 but are demonstrable
in vivo as well. In a previous study on rats with an albu-
min-coated extracorporeal tube running from the
carotid artery to the distal femoral artery we continu-
ously measured aggregate formation and found that
U se of extracorporeal systems in cardiopulmonarybypass and dialysis often causes such adverse sys-
temic effects as complement activation and bleeding
disorders. These effects are generally believed to result
largely from blood-material contact. Bleeding disorders
have been attributed to thrombocytopenia and platelet
dysfunction caused by platelet adhesion1,2 and contact
activation.3-5 Coating the system with heparin reduces
complement activation,6-8 platelet adhesion,9-11 and
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platelets easily aggregate in areas of increased shear
stress caused by partial occlusion of the tube.22
In this study we therefore tested the hypothesis that in
a coated extracorporeal system the roller pump also
evokes platelet aggregation. Albumin was employed as
the coating to avoid possible direct effects of surface-
bound heparin on platelets. Albumin coating has been
reported to be as effective as heparin coating in pre-
venting platelet aggregation and activation as a result of
blood-material contact.2,9,10,23 To elucidate the role of
shear stress we studied whether pump-induced platelet
aggregation could be prevented with aurintricarboxylic
acid (ATA), a synthetic triphenylmethane dye that
specifically prevents shear-induced platelet aggregation
without affecting aggregation induced by ADP, colla-
gen, epinephrine, thrombin, or arachidonic acid.24,25
Experiments were done with human blood in vitro and
with rat blood in vitro and in vivo.
Methods
Blood collection for in vitro experiments
Human blood. With an 18-gauge needle 10 mL blood was
collected from the antecubital veins of medication-free
healthy volunteers. After the first drops were discarded the
blood was allowed to flow in an albumin-coated tube that
contained 1 mL heparin solution (50 IU/mL). Values (mean ±
SEM) for pH, PCO2, and PO2 were 7.35 ± 0.01, 50.2 ± 1.5 mm
Hg, and 30.1 ± 2.5 mm Hg, respectively.
Rat blood. Male Wistar rats (325-400 g) were anesthetized
with an intramuscular bolus of ketamine (10%, 60 mg/kg,
Kombivet) and subsequent intraperitoneal administration of
pentobarbital (Nembutal, 25 mg/kg). After cannulation of a
common carotid artery, the animals received heparin (800
IU/kg) and 10 to 12 mL blood was slowly collected in a
syringe. Values (mean ± SEM) for pH, PCO2, and PO2 were
7.37 ± 0.01, 42.5 ± 1.5 mm Hg, and 74.4 ± 3.4 mm Hg,
respectively.
Setup for in vitro experiments. To study the influence of
the pump on platelet behavior we used a device in which
blood flow was generated either by gravity or by a pump (Fig
1). This setup consisted of 2 syringes positioned at different
heights and connected by medical-grade polyvinyl chloride
tubing (1.5 mm inner diameter, 100 cm long). Halfway along
this tube a piece of pump tube (1.65 mm inner diameter, 7 cm
long; Gilson, Inc, Middleton, Wis) was inserted and loosely
placed in a small noncommercial roller pump with rotator
and roller diameters of 35 and 6 mm, respectively. At 10 cm
from the pump the polyvinyl tube was serially connected to a
glass capillary tube (0.6 mm inner diameter) on the stage of a
microscope for continuous measurement of platelet aggrega-
tion, as has been described previously.22 The system was
filled with 7 to 8 mL blood. The difference in height between
the 2 syringes (30 cm) caused a flow of approximately 6
mL/min that lasted about 1 minute; at that point the nearly
empty upper syringe was automatically lowered with an elec-
tromotor and the full syringe was elevated to continue flow.
In this way there was no need to decant the blood and contact
of blood with air was minimized. To replace gravitational
flow by pump flow a calibrated screw on the pump was tight-
ened to set the pump so that it was just occlusive for blood.
Fig 1. Setup for in vitro experiments. Blood flow was generated either by gravity or by roller pump. Gravitational
flow was maintained by servo-controlled up-and-down motion of open syringes at each tube end (arrows). For
pump perfusion one tube end was disconnected from syringe and put in other syringe and pump was started after
tightening its rollers. Platelet aggregation was continuously monitored in an albumin-coated glass capillary insert-
ed in circuit and placed on microscope stage. Changes in light transmission from passage of aggregates were
detected by photodiodes.
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Then a tube end was detached and placed into the other reser-
voir and the pump was started. The whole system was either
coated with albumin or not coated and was placed in a poly-
methyl methacrylate (Perspex; ICI Acrylics, Inc, Nederland,
Tex) box with the temperature regulated at 32°C ± 1°C. The
method of coating has been described previously.26 Tests with
radioactively labeled albumin showed that the coating con-
sisted of 1 to 2 monolayers and was stable during at least 4
hours of blood perfusion.
In vivo experiments. Anesthesia was induced in rats as
described previously and maintained by continuous intraperi-
toneal infusion of 10 to 14 mg · kg–1 · h–1 pentobarbital with
a Harvard infusion pump (model 11; Harvard Apparatus, Inc,
Holliston, Mass). After tracheotomy the animals’ lungs were
ventilated with a mixture of room air and oxygen (3:1) at a
rate of 90 breaths/min. Tidal volume was adjusted so that
PaCO2 was approximately 40 mm Hg. Arterial pH ranged
from 7.33 to 7.42 and PaO2 ranged from 76 to 110 mm Hg.
Body temperature was measured with a rectal probe and kept
at 37.5°C by a means of servo-controlled heating pad.
After cannulation of the central part of a common carotid
artery (20 gauge) and the distal part of the left femoral artery
(22 gauge) the cannulas were connected with medical-grade
polyvinyl chloride tubing (1.5 mm inner diameter, 30 cm
long) filled with heparinized saline solution. During the con-
nection procedure flow to the leg was interrupted for 2 to 3
minutes only. Part of the tube was loosely positioned in the
roller pump. If the tube in the pump was not compressed,
blood flowed spontaneously (2-4 mL/min) as a result of the
difference between central carotid arterial and distal femoral
arterial pressures. For transition to pump flow the tube was
gradually compressed until flow stopped, and the pump was
then started. Platelet aggregation in the tube between the
pump and the femoral artery was continuously measured with
the same photometric device used in the in vitro experiments.
The whole system was coated with albumin. Aortic pressure
was measured through a stainless steel T-piece inserted in the
tube about 3 cm from the carotid cannula. Flow in the tubing
was measured with a perivascular flow probe. A warming
lamp above the extracorporeal circuit prevented the blood
from cooling more than about 1°C.
All animal handling was in compliance with the “Guide for
the Care and Use of Laboratory Animals” prepared by the
Institute of Laboratory Animal Resources, National Research
Council, and published by the National Academy Press,
revised 1996.
Measurement of platelet behavior. The device for contin-
uous detection of platelet aggregates has been described pre-
viously.22 Passage of aggregates through the glass capillary
tube was indicated by short-duration voltage peaks from pho-
tocells. For quantification the signals were converted to uni-
form spikes with a spike processor and subsequently counted
during fixed periods. In the in vivo experiments aggregate
formation was related to the value found after injection of 2
ng ADP into the tube a few centimeters from the carotid can-
nula. The 2 ng ADP was dissolved in 20 µL saline solution
and injected within half a second. This dose elicited strong
platelet aggregation that just barely did not impede flow.
Periodic inspection of blood samples under a microscope
confirmed the results obtained with the continuous aggre-
gometer; it also showed that aggregates seldom contained any
leukocytes and that aggregates of fewer than 4 platelets were
not detected.
For platelet counting and visual inspection of aggregates
0.1 mL blood was withdrawn from a syringe in the in vitro
experiments and from the T-piece in the extracorporeal shunt
in vivo. The blood was added to 150 m L of a solution of eth-
ylenediaminetetraacetic acid (3.6 mg/mL saline solution),
resulting in a final concentration of 6.6 mmol/L, to stabilize
the number of platelets and aggregates. From the ethylenedi-
aminetetraacetic acid–diluted sample, 20 m L was added to 2
mL Thromboplus (Sarstedt, Nürembrecht, Germany). Aggre-
gates and platelets were counted in a Bürker counting cham-
ber under phase contrast microscopy (· 400). Platelets were
also counted with a Coulter Counter (model ZF; Coulter
Corporation, Hialeah, Fla). Hemolysis was quantified by col-
orimetric determination of free hemoglobin in plasma at 600
nm (procedure No. 527; Sigma Chemical Co, St Louis, Mo).
Aurintricarboxylic acid. A trisodium salt of ATA (Aldrich
Chemical Company, Bornem, Belgium) was dissolved (30
mg/mL) in phosphate buffer (pH 7.4). In the in vivo experi-
ments 35 mg/kg was infused intravenously within 10 minutes
in rats that had not been earlier exposed to pump perfusion.
In a previous study22 this dose had been found to effectively
inhibit platelet aggregation in rats in which a mean shear
stress of 231 dyne/cm2 was generated by partial occlusion of
a tube between the carotid artery and the femoral artery. In
the in vitro experiments final concentrations of 1 mg/mL in
rat blood and 100 m g/mL in human blood24,25 were used.
Statistics. All values are expressed as mean ± SEM. Data
were analyzed by 2-way analysis of variance. If a significant
P value was present posttests for comparison between condi-
tions (pump or no pump) at different times were performed
with the Bonferroni multiple comparison procedure.
Results
Platelet aggregation in vitro and in vivo. Gravi-
tational flow of rat blood through an uncoated tube (n =
7) immediately resulted in strong platelet aggregation
(Fig 2, A). After 1.5 to 2 minutes aggregation decreased
and remained more or less stable. Starting the pump 10
minutes later did not elicit additional aggregation. On
the other hand, aggregation was absent or negligible
during gravitational flow in albumin-coated tubes (Fig
2, B); this could even be maintained for longer than 1
hour and demonstrates the effectiveness of albumin
coating to prevent platelet activation. The effect of start-
ing the pump in a coated system in vitro, also illustrat-
ed in Fig 2, B, was immediate and strong aggregation.
In addition, in vivo in rats with a coated tube between
the carotid artery and the femoral artery no aggregation
was observed with autoperfusion but aggregation start-
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ed when the pump was turned on (Fig 3, A). In all exper-
iments aggregation diminished after some minutes and
thereafter stabilized at a lower level, which was main-
tained for the period of observation (60 minutes in vitro
and 120 minutes in vivo). The pump start caused aortic
pressure to decline from 125 ± 5 mm Hg to 115 ± 6 mm
Hg within 15 minutes, after which it remained stable.
Reversal of pump perfusion to autoperfusion in vivo
stopped the aggregation, indicating that the aggregates
did not recirculate but probably either got stuck in the
capillary bed of leg or lungs or disaggregated.
The amount of pump-induced platelet aggregation in
coated tubes is quantitated in Fig 4. Aggregation in rat
blood in vitro (B) and in vivo (C) was more pronounced
and longer lasting than that in human blood in vitro (A).
Role of shear stress in pump-induced platelet aggre-
gation. In both the in vivo and the in vitro experiments
ATA effectively prevented aggregation by pump perfu-
sion (Fig 3, B, and Fig 4). In the in vivo experiments
platelets started to aggregate more and more as the effect
of ATA was wearing off after 1 to 1.5 hours. At the dose
used ATA did not change aortic pressure or heart rate.
Fig 2. A, In vitro platelet aggregation during gravitational flow of rat blood in uncoated tube. Blood was added
to system at time 0. B, Absence of platelet aggregation in vitro in albumin-coated tube during gravitational flow
and occurrence of aggregation at start of pump perfusion (arrow). Upper tracing shows signals from device mea-
suring passage of platelet aggregates, middle tracing shows quantitation of these signals in 30 seconds, and lower
tracing shows flow in system. Note that gravitational flow is bidirectional and pump flow is unidirectional.
A B
Fig 3. A, In vivo platelet aggregation in albumin-coated tube at start of pump perfusion (arrow). Pump flow was
set equal to spontaneous flow. B, Inhibition of pump-induced platelet aggregation by ATA. Middle tracings show
recorded signals, upper tracings show number of aggregates as percentage of value found after injection of 2 ng
ADP into tubing, and lower tracings show aortic pressure.
A B
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Platelet counts in vitro. During gravitational flow in
coated tubes platelet count showed a small and gradual
decrease during a period of 60 minutes (Fig 5) and no
aggregation was observed. By contrast, when the pump
was started after 10 minutes of gravitational flow (Fig
5), platelet count significantly (P = .0001) decreased
within 5 minutes in both human and rat blood. A fur-
ther gradual decrease, similar to that noticed with grav-
itational flow, was seen thereafter. With ATA (n = 3)
platelet counts after 60 minutes of pumping had dimin-
ished less than without ATA (78% ± 3% in human
blood and 72% ± 4% in rat blood).
In uncoated tubes (n = 7) rat platelet number fell to
78% ± 5% of control values within the first 10 minutes
of gravitational flow. When the pump was started the
count stabilized at about 62% within 20 minutes.
As appeared from platelet counts in blood that was
kept 1 hour in Eppendorff vials, human platelets (loss
to 78% ± 4% of control value, n = 11) seemed to be
more vulnerable than rat platelets (loss to 99% ± 9% of
control value, n = 22). Initial platelet counts for rat
blood were more than 5 times the counts in human
blood (1039 ± 65 · 109 cells/L vs 187 ± 17 · 109
cells/L).
Conditions for pump-induced platelet aggrega-
tion. The pump-induced aggregation in vitro could
only be observed when blood was handled with great
care during the preparation procedure. It was often
absent after contact of the blood with air or uncoated
material, use of too much heparin, blood loss during
cannulation, or vacuum sucking during blood collec-
tion. All these conditions caused platelet aggregation
and platelet loss, as judged by microscopic inspection
of the blood immediately after collection. Moreover,
Fig 4. Occurrence of platelet aggregation during pump
perfusion (arrows) in albumin-coated tube (filled diamonds)
and its prevention with ATA (filled squares). Data points
represent means; error bars represent SEM. A, Human blood
in vitro (without ATA, n = 6; with ATA, n = 3). B, Rat blood in
vitro (without ATA, n = 9; with ATA, n = 3). C, Rat blood
in vivo (without ATA, n = 5; with ATA, n = 3).
A
B
C
Fig 5. Platelet loss with pump perfusion (filled squares) and
without pump perfusion (filled diamonds) in albumin-coated
tube in vitro. Data points represent means; error bars repre-
sent SEM. Asterisk indicates significant difference between
concomitant time points of pump flow and gravitational flow.
A, Human blood (with pump, n = 8; without pump, n = 3). B,
Rat blood (with pump, n = 8; without pump, n = 7).
A
B
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experiments with human blood (n = 5) anticoagulated
with 3.8% citrate, which does not inhibit agonist-
induced platelet aggregation, showed that pump-
induced platelet aggregation was absent after even par-
tial calcium chelation.
The importance of the occlusion setting of the pump
was tested in vitro with rat blood (n = 3) by intention-
ally increasing its compression onto the tube. This was
done at 20 minutes after the start of pump perfusion,
when the initial pump-induced aggregation had leveled
off. Elevated compression caused a gradual and contin-
uous increase of aggregation that was clearly distinct
from the immediate and temporary aggregation
induced with the pump set to be just barely occlusive as
in the other experiments. This effect was probably
caused by hemolysis because in the experiments with
increased compression the mean increase in plasma
free hemoglobin levels after 60 minutes of pumping
was 121 ± 32 mg/dL, whereas this value was 26 ± 13
mg/dL in the in vitro experiments in which the pump
was set to be just barely occlusive (n = 9). In the in vivo
experiments the increase in plasma free hemoglobin
level after 2 hours of pump perfusion was less than 1.32
± 2.5 mg/dL (n = 5).
Discussion
Our results show that with human blood in vitro and
with rat blood both in vitro and in vivo the use of roller
pumps in albumin-coated extracorporeal systems caus-
es platelet aggregation, even when hemolysis is negli-
gible, and that elevated shear stress may be involved.
Pump-induced platelet aggregation appeared to be a
sensitive reaction. It was demonstrable only in coated
circuits and when the blood was handled with great
care. It could not be evoked after premature platelet
activation by contact with uncoated material, vacuum
suction of the blood, or contact with air. It was also
absent after partial calcium chelation with 3.8% citrate,
suggesting that shear stress is a weaker stimulus for
platelet aggregation than are the agonists used to test
platelet reactivity in vitro. The clinical situation in
which blood is heparinized and coated systems are
increasingly used seems to present conditions under
which pump-induced platelet aggregation is likely to
occur. Although roller pumps in the clinical setting dif-
fer from the small pump used in our experiments, we
think that pumps with characteristics different from
ours will elicit platelet aggregation as well because
aggregation was demonstrable already by gentle repet-
itive squeezing of the tube with the fingers.
Contact of blood with our uncoated tubes caused
immediate strong platelet aggregation and platelet loss,
confirming that this occurrence is a “first pass” effect.17
It may even be stronger in the uncoated capillary tubes
of clinically used filters, oxygenators, and artificial kid-
neys. The last, for example, have a surface to blood vol-
ume ratio of 163 cm2/mL, whereas in our system corre-
sponding values were 26 cm2/mL for the in vitro
experiments and 12 cm2/mL for the in vivo experiments.
Our finding that the pump-induced aggregation could
be prevented with ATA suggests that elevated shear
stress plays a prominent role because ATA specifically
inhibits shear-induced platelet aggregation by binding to
the von Willebrand factor but does not suppress the reac-
tions of platelets to other agonists.24,25 The ATA dose
used in this study has been shown to inhibit platelet
aggregation caused by a shear stress of 231 dyne/cm2,
which resulted from partial tube occlusion. In addition to
shear stress pumping may have caused the release of
platelet-activating substances from red blood cells as a
result of hemolysis. Although this is a real possibility in
clinical cardiopulmonary bypass, in which the increase
in plasma free hemoglobin levels usually varies from 26
to 82 mg/dL,27,28 it seems a less likely cause of platelet
aggregation in our experiments. The increase in plasma
free hemoglobin in our in vivo experiments was less than
1.32 mg/dL, indicating that hemolysis was limited. Even
in our in vitro setup, in which erythrocytes probably
were more vulnerable, free plasma hemoglobin concen-
tration only increased to values in the lower range of
those seen in clinical practice. Moreover, the time course
of platelet aggregation caused by hemolysis could be
distinguished from that related to elevated shear stress in
our experiments. When we intentionally augmented
hemolysis by tightening the rollers of the pump platelet
aggregation increased slowly and steadily, whereas
aggregation caused by pumping at the proper setting was
a short lasting phenomenon.
Pump-induced aggregation could be prevented with
ATA, which also attenuated the loss of platelets.
Whether ATA in its commercially available form can be
employed in human beings is not known, although sev-
eral authors suggest its potential usefulness21 and no
toxic effects have been found in dogs.25 Nevertheless,
it might be safer to develop substances that are more
specifically suited for human use. Like ATA, these sub-
stances should reversibly inhibit the binding of von
Willebrand factor to platelet glycoprotein Ib receptors.
One could think of recombinant fragments of von
Willebrand factor–like VCL (leucine504-lysine728), a
peptide which binds to glycoprotein Ib receptors in
human blood.29 In an experiment on a rat in vivo we
used VCL (gift of Professor J. J. Sixma, University
Hospital, Utrecht, The Netherlands). In the final con-
centration used (about 2 m mol/L) VCL largely prevent-
ed platelet aggregation during pumping in vivo.
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Our results show that the use of a roller pump in
extracorporeal circuits causes platelet aggregation.
This seems to be the result of elevated shear stress in
the blood within the pump tube because the platelet
aggregation can be prevented with ATA. Our results
also indicate that the effects of pumping on platelets are
masked in uncoated circuits because of the dominant
influence of blood-material contact.
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